nach oben

Trials

Erschienen in:

Open Access 01.12.2015 | Poster presentation

Introducing framework for analyzing non-adherence (FAN)

verfasst von: Ernest Edifor, Sharon Kean, Jane Aziz

Erschienen in: Trials | Sonderheft 2/2015

Einloggen, um Zugang zu erhalten

Excerpt

The importance of patient adherence to treatment medication cannot be over emphasised. Some authors have claimed adherence is the secret to a successful clinical trial; intuitively, non-adherence can lead to a trial failure. Non-adherence in clinical trials does not only blur drug efficacy results but could also have huge financial implications; research efforts are incessantly being made to find a “cure” to it. …

Titel: Introducing framework for analyzing non-adherence (FAN)
verfasst von: Ernest Edifor
Sharon Kean
Jane Aziz
Publikationsdatum: 01.12.2015
Verlag: BioMed Central
Erschienen in: Trials / Ausgabe Sonderheft 2/2015
Elektronische ISSN: 1745-6215
DOI: https://doi.org/10.1186/1745-6215-16-S2-P32

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Introducing framework for analyzing non-adherence (FAN)

Excerpt

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2015

Dose transition pathways: a design, analysis and operational tool for dose-finding trials using model-based designs

Conducting a randomised trial during an influenza pandemic: an example of a trial set up and ‘hibernated’ ready to activate and recruit within 4 weeks

What is the effect of patient-reported outcome (PRO) item order on prioritisation of PROs in the development of a core outcome set?

Do people who choose their treatment in a large randomised trial with parallel preference groups differ at baseline from those who agree to random treatment allocation? Results from the protect study

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials

Combining multiple predictive markers in stratified medicine